Niosomal plumbagin with reduced toxicity and improved anticancer activity in BALB/C mice.
Plumbagin niosome were prepared using a lipid layer hydration method, and drug entrapment was measured. The acute toxicity studies were conducted following treatment with free and niosomal plumbagin. The antitumour activity of niosomal plumbagin in a solid tumor (sarcoma-180) and Ehrlich ascites model was evaluated. Niosome-encapsulated plumbagin was less toxic than free drug. The antitumour activity of the drug was also better after encapsulation. The better anticancer activity can be justified with the help of LD50 survival studies and study of tumour volume doubling time.
Naresh
R A
RA
College of Pharmaceutical Sciences, KMC, Manipal, India.
Udupa
N
N
Devi
P U
PU
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use* / Q000633:toxicity; D002214:Capsules; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000473:pathology; D002626:Chemistry, Pharmaceutical; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000008:administration & dosage; D004354:Drug Screening Assays, Antitumor; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D009285:Naphthoquinones / Q000627:therapeutic use* / Q000633:toxicity; D012510:Sarcoma 180 / Q000188:drug therapy / Q000473:pathology; D013501:Surface-Active Agents / Q000494:pharmacology
D000972:Antineoplastic Agents, Phytogenic; D002214:Capsules; D004337:Drug Carriers; D008081:Liposomes; D009285:Naphthoquinones; D013501:Surface-Active Agents; C014758:plumbagin